Patent ID: 11872220
Assignee: JANSSEN PHARMACEUTICA NV
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 18:
19. A method of reducing levels of regulatory T cells in a subject having a malignancy, said method comprising:
administering, to said subject having the malignancy, a combination therapy comprising: (i) an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) having the structure of Formula (I), , or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and (ii) an inhibitor of an anti-apoptotic Bcl-2 family protein, wherein the combination therapy is administered to the subject in an amount effective to reduce regulatory T cell levels in the subject relative to the levels of regulatory T cells in the subject prior to said administering.